Harbour BioMed Wins $20 Million Patent Verdict Against Amgen

Editor’s Take: This decision could have wider ramifications across the global biotechnology sector by reinforcing legal protections for antibody-discovery platforms, an area that underpins many next-generation biologic drugs. 

A U.S. jury has found Amgen Inc. liable for patent infringement against Harbour BioMed in a closely watched biotechnology dispute, awarding the drug developer $20.2 million in damages and potentially setting the stage for higher penalties. 

The verdict, delivered by a jury in the U.S. District Court for the District of Delaware following a trial that began June 8, 2026, concluded that Amgen and its subsidiary Teneobio willfully infringed a key patent covering Harbour’s antibody-discovery technology. 

Jurors unanimously upheld the validity of the patent—known as the Grosveld patent—and determined that Amgen’s infringement was deliberate, a finding that could allow the court to triple the damages to as much as roughly $60.6 million if the judge agrees.  

About the Case 

The case, filed in 2021 by Harbour Antibodies, centered on intellectual property tied to the company’s proprietary transgenic rodent platform used to generate fully human antibodies, technology that has become increasingly valuable in developing treatments for cancer, immune diseases and other conditions. 

The ruling represents a rare full victory for a smaller biotechnology firm against a major pharmaceutical company in Delaware, a venue known for complex patent litigation but relatively infrequent large jury awards. 

Harbour BioMed said the decision validates its technology platform and strengthens its broader intellectual-property portfolio. The company indicated it intends to continue pursuing enforcement efforts related to other patents, including one it says could carry significantly larger financial implications.  

“This is an epic victory for Harbour BioMed, reaffirming the company as the true innovator behind this transformative technology,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “The jury’s finding of willful infringement sends a clear message that scientific innovation must be respected, regardless of the size of the company behind it. It demonstrates our resilience, strategic discipline, and unwavering commitment to ensuring that groundbreaking scientific contributions are recognized, respected, and fairly compensated. This textbook victory in the patent battle will also mark a new chapter for the global antibody patent landscape.” 

Amgen did not immediately respond to the verdict in the press release issued by Harbour BioMed. The case may still see post-trial motions or appeals, which are common in high-stakes patent disputes. 

For now, the verdict marks a decisive legal win for Harbour BioMed and highlights the intensifying competition over foundational technologies in the multibillion-dollar market for antibody therapeutics.